Comparative evaluation of the chemotherapeutic efficacies of two salts of diminazene aceturate in Trypanosoma brucei brucei infected dogs

Author:

Eze Ukamaka U.,Eke Ifeanyi G.,Ezeh Ikenna O.,Nzeakor Terry A.,Owube Callistus,Dede Ann,Anene Boniface M.

Abstract

Purpose: To compare the anti-trypanosomal efficacies of 4,4-(diazoaminedibenzamidinetrihydrate) diacetate (4,4-DDBT) and 4,4-(diazoamino) benzamidine (4,4-DB) in experimental canine trypanosomosis. Methods: The efficacies of 4,4-DDBT and 4,4-DB were evaluated in 4 groups of dogs (n = 3) designated A-D. Group A was normal control without infection or drug treatment, group B did not receive any drug treatment but was infected with Trypanosoma brucei brucei, while groups C and D were infected with T. b. brucei and treated with 4,4-DDBT(3.5 mg/kg) and 4,4-DB (3.5 mg/kg), respectively. Results: The incubation period of the infection was 6 - 9 days post-infection. Treatment of the dogs with 4,4-DDBT led to zero parasitaemia 48 h post-treatment, while there was only a decrease in parasitemia to log 6 in 4,4-DB-treated dogs. Resurgence of parasite into the blood stream occurred in 4,4-DDBTtreated dogs 6 days after initial parasite clearance. Blood analyses post-treatment revealed elevated leucocytes and lymphocytes in 4,4-DB-treated dogs (p < 0.05). Packed cell volume was also observed to be higher in 4,4-DDBT-treated group when compared to 4,4-DB group (p < 0.05). Conclusion: These findings suggest that 4,4-DDBT is more efficacious in the clinical management of canine trypanosomosis caused by T. b. brucei. However, it does not prevent relapse of infection. Based on these findings, therefore, 4,4-DDBT should be the diminazene salt of choice when indicated in the clinical management of T. b. brucei infection in dogs.

Publisher

African Journals Online (AJOL)

Subject

Pharmacology (medical),Pharmaceutical Science

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3